

## **SWIXX AND BEIGENE PARTNER IN 13 COUNTRIES OF CENTRAL AND EASTERN EUROPE, GREECE, CYPRUS AND MALTA**

**SWIXX ANNOUNCEMENT NO. 54**

**May 9<sup>th</sup>, 2023**

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of an Exclusive Distribution Agreement with BeiGene Switzerland GmbH. Under the Agreement, Swixx is appointed to carry out distribution and promotion activities for BRUKINSA<sup>®</sup> (zanubrutinib) in the territory of Bulgaria, Croatia, Czech Republic, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Romania, Slovakia and Slovenia.

In the European Union, BRUKINSA<sup>®</sup> as monotherapy is indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. BRUKINSA<sup>®</sup> as monotherapy is also indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Finally, BRUKINSA<sup>®</sup> as monotherapy is also indicated for the treatment of adult patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).<sup>1</sup>

“We are delighted to have been granted the opportunity to partner with BeiGene across thirteen countries in the CEE region”, said Dezso Martha, Chief Operating Officer of Swixx. “We are convinced that BRUKINSA<sup>®</sup>, as a next-generation Bruton Tyrosine Kinase inhibitor, brings an important addition to our growing hematology portfolio. Capitalizing on our strong presence in hematology and CEE, Greece, Cyprus and Malta, we look forward to working closely with BeiGene colleagues, as well as with the healthcare community to establish and expand patient access to BRUKINSA<sup>®</sup> in our markets as soon as possible. “

Dr. Laur Saar, Medical, Regulatory and Pharmacovigilance Director at Swixx, commented that “there remain significant unmet therapeutic needs for patients living with B-cell malignancies like chronic lymphoid leukemia. Thus, BRUKINSA<sup>®</sup> is a much-awaited therapeutic option which addresses unmet needs of eligible patients in various hematologic malignancies. Our strong, science-driven medical teams are eagerly anticipating to swiftly familiarize regions' healthcare professionals with the pivotal clinical data of BeiGene's targeted oral therapy. We are convinced that by working in partnership with BeiGene and the broad healthcare community we can improve patients' outcomes.”

Stefan Barbour, General Manager of the Sub Region Europe at BeiGene, which includes CEEG, emphasized that “the appointment of Swixx BioPharma as partner is an important milestone”. He affirms that “We will now start working with health authorities and healthcare communities in these 13 countries to follow through on our core commitment to patients. Cancer has no borders. Neither do we.”

### **About Swixx BioPharma AG**

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian countries including Belarus, Kazakhstan, Moldova and Uzbekistan. With over 1200 employees

and sales which exceeded 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma in the Central, Eastern and Southeastern regions of Europe. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

## About BeiGene

BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit [www.beigene.com](http://www.beigene.com) and follow us on Twitter at [@BeiGeneGlobal](https://twitter.com/BeiGeneGlobal).

**Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG**  
vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

## References:

<sup>1</sup>European Medicines Agency, Summary of product characteristics, Brukinsa® (zanubrutinib). Available at: [https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/brukinsa-epar-product-information_en.pdf). Last accessed: April 2023.